Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 4:52 AM ET

Biotechnology

Company Overview of ARCA biopharma, Inc.

Company Overview

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. The company has a collaboration agreement with Medtronic, Inc. for the support of Gencaro’s Phase IIB/III clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

11080 CirclePoint Road

Suite 140

Westminster, CO 80020

United States

16 Employees

Phone:

720-940-2200

Fax:

720-208-9261

Key Executives for ARCA biopharma, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 70
Total Annual Compensation: $300.7K
Senior Vice President, General Counsel and Secretary
Age: 56
Total Annual Compensation: $285.6K
Compensation as of Fiscal Year 2014.

ARCA biopharma, Inc. Key Developments

ARCA biopharma, Inc. Provides an Update on GENETIC-AF

ARCA biopharma, Inc. provided an update on GENETIC-AF, the company's Phase 2B/3 clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential genetically-targeted treatment for the prevention of atrial fibrillation. 50 patients have been enrolled in the GENETIC-AF trial. By the end of 2016, the company anticipates enrollment of a sufficient number of patients for the Data Safety Monitoring Board (DSMB) interim analysis of Phase 2B efficacy data. Allowing for patients to complete their 24-week treatment period, the outcome of the DSMB interim analysis is expected in the first half of 2017. There are currently 60 clinical trial sites in the United States and Canada, with 5 additional sites in start-up. GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL (metoprolol succinate) for the treatment of atrial fibrillation (AF) in patients with heart failure and left ventricular systolic dysfunction (HFREF patients). The primary endpoint of GENETIC-AF is time to symptomatic AF/atrial flutter (AFL). ARCA is enrolling only HFREF patients with the genetic variant of the cardiac beta-1 adrenergic receptor, which the Company believes responds most favorably to Gencaro, the 389 arginine homozygous genotype (ADRB1 Arg389Arg). GENETIC-AF has an adaptive design, under which the company initiated the trial as a Phase 2B trial. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3. The Company expects GENETIC-AF will enroll a combined 620 patients over the Phase 2B and Phase 3 portions of the trial.

ARCA biopharma, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-01-2015 08:10 AM

ARCA biopharma, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-01-2015 08:10 AM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Thomas A. Keuer, Chief Operating Officer.

ARCA Biopharma, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

ARCA biopharma, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of $2,817,000 against $2,285,000 a year ago. Net loss and comprehensive loss was $2,814,000 or $0.31 per basic and diluted share against $2,284,000 or $0.76 per basic and diluted share a year ago. For the nine months, the company reported loss from operations of $8,280,000 against $7,081,000 a year ago. Net loss and comprehensive loss was $8,277,000 or $1.54 per basic and diluted share against $7,078,000 or $2.44 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
IES Diagnostics Inc. United States
Protherics Inc. United States
Adnexus Therapeutics, Inc. United States
ZymoGenetics, Inc. United States
Pronutria Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 10, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ARCA biopharma, Inc., please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.